https://www.selleckchem.com/pr....oducts/pexidartinib-
55 vs 3.76, P .001; 3.55 vs 3.80, P= .001; 3.55 vs 3.99, P .001). The pediatric asthma impact survey scores improved from baseline to visits 2 and 3 (43.33 vs 34.08, P .001; 43.33 vs 31.74, P .001). ED visits and prednisone use significantly decreased from baseline to visits 2 and 3 (ED 0.46 vs 0.13, P= .03; 0.46 vs 0.02, P= .02; prednisone use, 0.49 vs 0.13, P= .02; 0.49 vs 0.03, P= .003. Satisfaction was high with mean client satisfaction questionnaire score of approximately 30 (out of 32) at all visit